Esophageal Cancer - Pipeline Review, H1 2014

  • Share on Google+

Global Markets Direct

2014 Jun 30

208 Pages (PDF)




Esophageal Cancer - Pipeline Review, H1 2014

Summary

Global Markets Directs, Esophageal Cancer - Pipeline Review, H1 2014, provides an overview of the Esophageal Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Esophageal Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Esophageal Cancer - Overview 9
Pipeline Products for Esophageal Cancer - Comparative Analysis 10
Esophageal Cancer - Therapeutics under Development by Companies 11
Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes 15
Esophageal Cancer - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Esophageal Cancer - Products under Development by Companies 20
Esophageal Cancer - Products under Investigation by Universities/Institutes 22
Esophageal Cancer - Companies Involved in Therapeutics Development 23
Bristol-Myers Squibb Company 23
Boehringer Ingelheim GmbH 24
Amgen Inc. 25
GlaxoSmithKline plc 26
Gilead Sciences, Inc. 27
Daiichi Sankyo Company, Limited 28
Novartis AG 29
Ono Pharmaceutical Co., Ltd. 30
CTI BioPharma Corp. 31
Genmab A/S 32
Advaxis, Inc. 33
Immunomedics, Inc. 34
Takara Bio Inc. 35
Synta Pharmaceuticals Corp. 36
Transgene Biotek Limited 37
Supratek Pharma Inc. 38
Glycotope GmbH 39
Hutchison MediPharma Limited 40
Advantagene, Inc. 41
CerRx, Inc. 42
Cerulean Pharma, Inc. 43
MacroGenics, Inc. 44
Merrimack Pharmaceuticals, Inc. 45
Omnitura Therapeutics Inc. 46
Omeros Corporation 47
Oncolys BioPharma Inc. 48
ImmunoFrontier, Inc. 49
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 50
Mebiopharm Co., Ltd. 51
Kite Pharma, Inc. 52
Aslan Pharmaceuticals Pte. Ltd. 53
Precision Biologics, Inc. 54
Esophageal Cancer - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Combination Products 56
Assessment by Target 57
Assessment by Mechanism of Action 61
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
nimotuzumab - Drug Profile 69
paclitaxel poliglumex - Drug Profile 72
ganetespib - Drug Profile 76
varlitinib - Drug Profile 80
doxorubicin nanoformulation - Drug Profile 82
CRLX-101 - Drug Profile 84
MM-111 - Drug Profile 86
afatinib - Drug Profile 88
MBP-426 - Drug Profile 91
nivolumab - Drug Profile 93
IMF-001 - Drug Profile 97
margetuximab - Drug Profile 99
Vaccine for Oncology - Drug Profile 101
Anti-NY ESO-1 Lymphocytes Vaccine - Drug Profile 102
HLA-A2402 Restricted Epitope Peptide URLC10, CDCA1, KOC1 Vaccine - Drug Profile 103
AMG-337 - Drug Profile 104
IMMU-132 - Drug Profile 105
rhLT28-171 - Drug Profile 106
Cell Therapy Targeting NY-ESO-1 for Oncology - Drug Profile 107
fenretinide - Drug Profile 108
OBP-301 - Drug Profile 110
binimetinib - Drug Profile 111
BYL-719 - Drug Profile 115
LJM-716 - Drug Profile 117
patritumab - Drug Profile 119
HuMax-TF-ADC - Drug Profile 121
BMS-833923 - Drug Profile 122
HMPL-813 - Drug Profile 124
cetuximab biobetter - Drug Profile 125
GSK-2256098 - Drug Profile 126
TBI-1201 - Drug Profile 127
Autologous Tumor Cell Vaccine + [celecoxib] - Drug Profile 129
DKN-01 - Drug Profile 130
Recombinant Adenoviral Human p53 Gene Therapy - Drug Profile 132
OMN-54 - Drug Profile 133
ADXS-HER2 - Drug Profile 135
NEO-201 - Drug Profile 136
TBL-0805E - Drug Profile 138
Drug For Esophageal Cancer - Drug Profile 139
First Generation Attenuated Strain Of Reovirus - Drug Profile 140
rAAV-VICN003 - Drug Profile 141
1-BB1 - Drug Profile 142
Small Molecule To Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile 144
Histone Demethylase Inhibitors for Esophageal Cancer - Drug Profile 145
Esophageal Cancer - Recent Pipeline Updates 146
Esophageal Cancer - Dormant Projects 194
Esophageal Cancer - Discontinued Products 195
Esophageal Cancer - Product Development Milestones 196
Featured News & Press Releases 196
Appendix 204
Methodology 204
Coverage 204
Secondary Research 204
Primary Research 204
Expert Panel Validation 204
Contact Us 205
Disclaimer 205
Bristol-Myers Squibb Company 
Boehringer Ingelheim GmbH 
Amgen Inc. 
GlaxoSmithKline plc 
Gilead Sciences, Inc. 
Daiichi Sankyo Company, Limited 
Novartis AG 
Ono Pharmaceutical Co., Ltd. 
CTI BioPharma Corp. 
Genmab A/S 
Advaxis, Inc. 
Immunomedics, Inc. 
Takara Bio Inc. 
Synta Pharmaceuticals Corp. 
Transgene Biotek Limited 
Supratek Pharma Inc. 
Glycotope GmbH 
Hutchison MediPharma Limited 
Advantagene, Inc. 
CerRx, Inc. 
Cerulean Pharma, Inc. 
MacroGenics, Inc. 
Merrimack Pharmaceuticals, Inc. 
Omnitura Therapeutics Inc. 
Omeros Corporation 
Oncolys BioPharma Inc. 
ImmunoFrontier, Inc. 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 
Mebiopharm Co., Ltd. 
Kite Pharma, Inc. 
Aslan Pharmaceuticals Pte. Ltd. 
Precision Biologics, Inc.				
Full Name
Email
Job Title
Mobile
Your Requirement
Full Name
Email
Job Title
Mobile
Your Requirement